Eosinophil-derived neurotoxin levels can predict allergic disease development and atopic march in children

Zak Callaway1,2, Chang-Keun Kim2

  • 1Science Division, Mahidol University International College, Mahidol University, Nakhon Pathom, Thailand.

PubMed

Insights

Eosinophil-derived neurotoxin (EDN) is a promising biomarker for predicting allergic diseases in children. Early measurement of EDN can help identify at-risk individuals and potentially halt the progression of atopic march.

Area of Science:

  • Immunology
  • Allergology
  • Pediatrics

Background:

  • Atopic march describes the progression of allergic diseases in children, starting with atopic dermatitis and potentially leading to asthma and rhinitis.
  • This progression involves shared genetic, environmental, and immunological factors, including T-helper type 2 responses, IgE production, and eosinophil activation.

Purpose of the Study:

  • To evaluate eosinophil-derived neurotoxin (EDN) as a reliable biomarker for atopic march-associated conditions.
  • To determine the predictive value of EDN levels for the development of allergic diseases.

Main Methods:

  • The study focused on analyzing eosinophil-derived neurotoxin (EDN) levels in children with atopic manifestations.
  • EDN levels were assessed in relation to the progression of atopic dermatitis, allergic asthma, and allergic rhinitis.

Main Results:

  • Elevated EDN levels were observed in a subset of patients with atopic march-associated conditions.
  • Increased EDN levels demonstrated predictive value for the development of allergic diseases, indicating its role in prognosis and diagnosis.

Conclusions:

  • Eosinophil-derived neurotoxin (EDN) is a promising biomarker for the prognosis, diagnosis, treatment, and monitoring of allergic diseases within the atopic march.
  • Early detection and management of elevated EDN levels may lead to better patient outcomes and potentially halt the progression of allergic diseases.

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
364
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Allergic Reactions02:06

Allergic Reactions

Overview
27.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
245